Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chimerigen
IL-15 (mutant) (human):Fc (human) (rec.)
490
CHF
CHF 490.00
In stock
CHI-HF-21015M-C05050 µgCHF 490.00
| Product Details | |
|---|---|
| Synonyms | Interleukin-15 |
| Product Type | Protein |
| Properties | |
| Source/Host | CHO cells |
| Sequence |
The extracellular domain of human IL-15 (aa 49-162) including mutations at Q149D and Q156D is fused to the N-terminus of the Fc region of human IgG1. |
| Crossreactivity | Human |
| Biological Activity |
This mutant IL-15/Fc fusion protein specifically binds to the IL-15R, competitively inhibits IL-15-triggered cell proliferation, promotes transplant tolerance, does not activate the STAT-signaling pathway, and exerts a prolonged circulating half-life caused by the modified Fc domain. |
| Purity | ≥98% (SDS-PAGE) |
| Endotoxin Content | <0.06EU/μg protein (LAL test; Lonza). |
| Reconstitution |
Reconstitute 50µg vial in 50µl sterile water. Add 1X PBS to the desired protein concentration. |
| Formulation | Lyophilized from 0.2μm-filtered solution in PBS. |
| Protein Negative Control | |
| Other Product Data |
NCBI reference NP_751914.1: IL-15 (human) |
| Declaration | Manufactured by Chimerigen. |
| Shipping and Handling | |
| Shipping | BLUE ICE |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
Avoid freeze/thaw cycles. Centrifuge lyophilized vial before opening and reconstitution. |
| Use/Stability |
Stable for at least 1 year after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C. |
| Documents | |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
Interleukin-15 (IL-15) has a broad spectrum of biological activities. It is crucial for the development, proliferation, survival and differentiation of multiple cells from both innate and adaptive immune systems. IL-15 up-regulation has a central role in the development of several autoimmune or chronic inflammatory disorders. Targeting IL-15 or its receptor may have a valuable impact on the treatment of immune-mediated diseases. IL-15 participates in the development of important immune antitumor mechanisms. It activates CD8(+) T cells, natural killer (NK) cells, NK T cells, and can promote the formation of antitumor antibodies. IL-15 can also protect T effector cells from the action of T regulatory cells and reverse tolerance to tumor-associated antigens. In pre-clinical studies IL-15 has been found to demonstrate potentiated antitumor effects following pre-association with IL-15Rα, or when used in combination with chemotherapy, adoptive therapy, monoclonal antibodies, and tumor vaccines.
Product References
- A Dual Action of Rheumatoid Arthritis Synovial Fibroblast IL-15 Expression on the Equilibrium between CD4+CD25+ Regulatory T Cells and CD4+CD25- Responder T Cells: M. Benito-Miguel, et al.; J. Immunol. 183, 8268 (2009)
- IL-2/α-IL-2 complex treatment cannot be substituted for the adoptive transfer of regulatory T cells to promote bone marrow engraftment: B. Mahr, et al.; PLoS One 11, e0146245 (2016)
Related Products
